HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5233705 compound

an Akt kinase inhibitor; structure in first source

Also Known As:

AKTIV compound; Akt inhibitor IV

Networked: 16 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Benzothiazoles: 40
        5233705 compound: 16
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - 5233705 compound: 16
    - Benzothiazoles: 40
      - 5233705 compound: 16

Experts

1.	Araldi, Dionéia: 1 article (10/2021)
2.	Bonet, Ivan J M: 1 article (10/2021)
3.	Green, Paul G: 1 article (10/2021)
4.	Khomula, Eugen V: 1 article (10/2021)
5.	Levine, Jon D: 1 article (10/2021)
6.	Chang, Rong: 1 article (01/2020)
7.	Gao, Gan: 1 article (01/2020)
8.	Liu, Xing: 1 article (01/2020)
9.	Wang, Chunsheng: 1 article (01/2020)
10.	Zhang, Yingwei: 1 article (01/2020)

Related Diseases

1.	Myocardial Infarction 01/01/2020 - "The results showed that fibrauretine can significantly reduce the myocardial infarction area in myocardial I/R injury, inhibit the activities of LDH and CK-MB in the serum, and increase the content of NO. However, the effects of fibrauretine on the reduction of the myocardial infarction area were eliminated by the PI3K inhibitor LY294002, Akt inhibitor IV, GR inhibitor RU468, ER inhibitor tamoxifen, eNOS inhibitor L-NAME and ERK1/2 inhibitor U0126. "
2.	Infarction (Infarctions) 12/01/2008 - "Akt inhibitor IV increased ischemic infarct volume and apoptotic-related DNA fragmentation. " 05/17/2011 - "The infarct size reduction effect of RSE was abolished by RU468 (an inhibitor of GR), tamoxifen (an inhibitor of ER), LY294002 (an inhibitor of PI3K), Akt inhibitor IV (an inhibitor of Akt protein kinase), U0126 (an inhibitor of Erk1/2) and NG-nitro-l-arginine methyl ester hydrochloride (an inhibitor of NOS), but not actinomycin D (an inhibitor of transcription process). "
3.	Hyperalgesia 06/01/2013 - "Pretreatment of rats with an intrathecal injection of Akt inhibitor IV blocked CFA-induced thermal hyperalgesia and CFA-induced increases in Nav1.7 and Nav1.8 in the L4/5 DRGs on day 7 after CFA injection. " 10/06/2021 - "Intradermal administration of inhibitors of mammalian target of rapamycin (mTOR; rapamycin) and protein kinase B (AKT; AKT Inhibitor IV), signaling molecules downstream of PI3Kγ, also attenuates HMWH-induced anti-hyperalgesia. "
4.	B-Cell Lymphoma (Lymphoma, B Cell) 10/01/2012 - "This up-regulated FMRP expression was abolished by pre-treatment with PI3K and Protein Kinase B (Akt) inhibitors: LY294002, Akt inhibitor IV, and VIII. Reduced FMRP expression in vitro or in vivo using small hairpin Fmr1 virus exacerbated cell death by glutamate or MCAO, presumably via hypophosphorylation of Akt and reduced expression of B-cell lymphoma-extra large (Bcl-xL). "
5.	Pain (Aches) 05/01/2010 - "Pain behavior was also reduced by spinal inhibition of phosphatidylinositol 3-kinase (PI-3K) (wortmannin; 1 and 5microg) and LY294002; 50 and 100microg) and Akt (Akt inhibitor IV; 3microg). "

Related Drugs and Biologics

1.	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
2.	NG-Nitroarginine Methyl Ester (L-NAME)
3.	Tamoxifen
4.	U 0126 (UO 126)
5.	Wortmannin
6.	Proto-Oncogene Proteins c-akt (Protein Kinase B)
7.	TOR Serine-Threonine Kinases
8.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
9.	Collagen Type I (Type I Collagen)
10.	Sirolimus (Rapamycin)

Related Therapies and Procedures

1.	Spinal Injections
2.	Intradermal Injections